von Willebrand factor (vWF), a multimeric protein that mediates platelet adhesion, circulates in association with the procoagulant Factor VIII (FVIII). In previous reports, plasmin was shown in vitro to inactivate FVIII and cleave the vWF subunit extensively, but to cause only a modest decrease in vWF platelet-agglutinating activity. In the present study, the digestion of vWF multimers by plasmin was analyzed by sodium dodecyl sulfate-agarose gel electrophoresis and radioimmunoblotting. In vitro, plasmin degraded the large vWF multimers to smaller forms that could be distinguished from the small multimers present before digestion only by a slightly increased electrophoretic mobility. These plasmin-cleaved "multimers" were composed of disulfide-linked fragments with no intact vWF subunits. Thus, many plasmin cleavages occur within disulfide loops. The slight increase in mobility of plasmin-digested vWF is in part explained by the early cleavage from the multimers of a 34,000-mol wt peptide, which was purified and partially sequenced. The amino-terminal sequence (33 residues) agrees with the previously reported sequence (15 residues) for the amino terminus of the intact vWF subunit. Analysis of plasmin-digested vWF allowed deduction of a model for the native vWF structure, including the approximate location of the interprotomer disulfide bond(s).
Introduction
Factor VIII/von Willebrand factor (FVIII/vWF)' is a plasma protein complex with two hemostatic functions. Although PAGE, polyacrylamide gel electrophoresis; SK, streptokinase; vWF, von Willebrand factor. present in only trace amounts in the complex, the FVIII protein possesses the procoagulant activity lacking in hemophilia A. vWF, which is deficient or defective in von Willebrand's disease, mediates platelet adhesion to subendothelium and platelet agglutination in the presence of ristocetin (1) . vWF circulates as a series of large multimers that range in size from -500,000-800,000 to 12-20 million mol wt, as estimated from electrophoretic mobilities in sodium dodecyl sulfate (SDS)-agarose or agarose-acrylamide gels (2) (3) (4) and from volumes on electron micrographs (5) . The smallest form of vWF seen in plasma (the protomer) appears to be a dimer of 200,000-280,000-mol wt subunits, whereas the larger forms are currently presumed to be oligomers of this dimer (3) .
Plasmin is a plasma serine proteinase responsible for thrombolysis. Its circulating zymogen form, plasminogen, is converted to plasmin by urokinase, by the streptokinaseplasminogen activator complex, as well as by other circulating or tissue-associated plasminogen activators. In vivo, the primary plasmin substrates are fibrin and fibrinogen. However, plasmin will selectively cleave arginyl-X and lysyl-X peptide bonds in other proteins in vitro. Several laboratories have described the effects of plasmin on FVIII/vWF (6) (7) (8) (9) . In these early studies, when purified FVIII/vWF was incubated with plasmin, FVIII clotting activity was destroyed within 5-15 min; however, the vWF ristocetin-cofactor platelet-agglutinating activity was relatively resistant, with -70% of the activity remaining even after 24 h of digestion (6, 9) . When plasmin-degraded FVIII/ vWF was examined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), after disulfide bond reduction, the vWF subunit was found to be cleaved into multiple fragments, ranging in molecular weight from 15,000 to 185,000, depending on the duration of digestion. There was not good agreement among the studies about the number of fragments in the terminal digest or their molecular weights. When nonreduced plasmindigested FVIII/vWF was analyzed, the protein did not enter 4-5% polyacrylamide gels to any significant extent (6) (7) (8) (9) , but by crossed immunoelectrophoresis, the mobility was increased (10) . Because the multimeric structure of vWF was not recognized at the time of those studies and in light of current, though still limited, understanding of vWF structure, we analyzed the effect of plasmin in vitro on vWF multimers and found that the pattern of degradation allowed several deductions about the structure of native vWF. In addition, we undertook to determine whether vWF is significantly degraded by plasmin in vivo, and unexpectedly found that a dramatic increase in the plasma vWF level occurred during thrombolytic therapy.
Purification ofFVIII/vWF. FVIII/vWF was purified from lyophilized intermediate purity (I 1) concentrates (American Red Cross) by polyethylene glycol 4000 precipitation and 4% agarose gel (Biogel A-15m; Bio-Rad Laboratories, Richmond, CA) chromatography as previously reported (12) . Protein concentration was determined by the method of Lowry et al. ( 13) .
Purification of plasminogen. Glu-plasminogen was obtained by affinity chromatography of fresh-frozen plasma on lysine-agarose (14) . Protein concentration was calculated using a molecular weight of 92,000 and an extinction coefficient (E280 nm) of 17 
Results
Plasmin degradation ofpurified FVIII/vWF Effect on vWF multimers. The time course of plasmin digestion of the purified vWF multimers, analyzed nonreduced by SDS-1.5% agarose gel electrophoresis and radioimmunoblotting, is shown in Fig 1 A . The most striking feature was the progressive loss of the larger multimers and concordant increase in smaller forms. There was also a loss of sharpness in the original triplet pattern which was prominent in our purified vWF. The plasmin-degraded multimers migrated slightly faster than the corresponding multimers in the control sample, which can be explained by the loss of a small peptide (34,000 mol wt) that was not seen on the large-pore agarose gels, but which was detected by SDS-PAGE of nonreduced samples. This fragment was much more prominent on Coomassie staining than on immunoblots, suggesting that it contains few binding sites for our rabbit antibody to native vWF. Trypsin also degraded vWF from larger to smaller multimers ( Fig. 1 B) , but much more rapidly than plasmin at the same molar concentration, which is consistent with the broader specificity of trypsin. Even with prolonged digestion and addition of more proteinase, vWF with fewer than three multimers was never produced by plasmin. In contrast, the terminal trypsin digest consisted of a major form that is smaller than the vWF protomer and many smaller fragments not visualized on agarose gels. The amount of radiolabeled antibody bound to each lane of the immunoblot shown in Fig. 1 A decreased during plasmin digestion, indicating gradual loss of antigenic sites (17% loss by 15 min, 31% by 5 h). In previous reports, when "FVIII-related" antigen (i.e., vWF antigen) was measured by rocket immunoelectrophoresis, the rocket height after plasmin digestion increased 200-500% (6, 7). Rocket immunoelectrophoresis may measure primarily the concentration of the fastest migrating form of vWF, which does increase dramatically as digestion proceeds (Fig. 1 A) . The Pattern of vWF subunit cleavage. Plasmin-and trypsindegraded purified FVIII/vWF were also analyzed by SDS-PAGE after disulfide bond reduction ( Fig. 1 C and D) . The major early plasmin digestion products were 134,000, 114,000, and 34,000 mol wt, with minor bands at 220,000, 168,000, 43,000, and 21,000 mol wt (Fig. C) . With further digestion, all forms larger than 134,000 mol wt disappeared and the concentration of the 134,000-and 1 14,000-mol wt bands decreased as the intensity of the bands at 78,000, 66,000, 60,000, 48,000, 43,000, and 21,000 mol wt increased. Comparison of the nonreduced and reduced patterns ( Fig. I A and  C) suggests that many of the plasmin cleavage sites lie within disulfide loops, in that the large multimers persisted long after the intact subunit (240,000 mol wt) had disappeared. Twodimensional SDS gel analysis of a 90-min digest (Fig. 2) shows conclusively that the plasmin-degraded vWF multimers are composed of multiple disulfide-linked fragments, rather than 240,000-mol wt subunits. The loss of the sharp triplet pattern seen on nonreduced gels (Fig. 1 A) is therefore not surprising. Of note, all of our purified FVIII/vWF preparations, even before plasmin treatment, contained variable amounts of a 168,000-mol wt band which is easily seen on immunoblots (Fig. 1 C, lane 1) and which intensified early in some plasmin least half of the vWF subunits during the 4 h digestion.
Plasmin degradation of FVIII/vWF in whole plasma in vitro Although plasmin will degrade purified FVIII/vWF, the latter may be poor plasmin substrates in a plasma milieu or in clots where the concentration of fibrinogen or fibrin, presumably the preferred substrates, overwhelms that of FVIII/vWF. Moreover, plasmin may be inhibited by plasma proteinase inhibitors before a secondary substrate such as FVIII or vWF can be cleaved. When whole plasma or plasma clots were treated with selected concentrations of either SK or urokinase for 1-12 h, no change in the vWF multimer pattern was discerned. That active plasmin was in fact generated was verified by the rapid lysis of the fibrin clots. Moreover, FVIII clotting activity of the plasma was destroyed (only 15% remained 15 min after addition of 100 U of SK per milliliter). To determine whether 
Acute effect of SK infusion on FVIII and vWF in vivo
Despite being unable to demonstrate plasmin degradation of vWF in whole plasma in vitro, we decided to examine the plasmas from patients receiving SK to determine whether multimer degradation occurred in vivo. A typical example of the acute effect of SK on the vWF multimers is shown in Fig.  5 . Although we anticipated that, as plasmin was generated, the Ser-Leu-Ser-Cys-Arg-Pro-Pro-Met-Val -Lys- 5 10 Leu-Val -Cys-Pro-Ala-Asp-Asn-Leu-Arg-Ala- 15 20 Gl u-Gly-Leu-Gl u-Cys-Thr-Lys-Thr-Cys-Gl n- 25 30 Asn-Tyr-Asp... multimers would be either unchanged or slightly degraded to smaller forms, we found instead that the level of vWF antigen (in all multimer sizes) was increased in 12 of 14 patients by 30 min after starting the SK and in all patients by 2 h. The changes in vWF antigen, platelet-agglutinating activity, and FVIII clotting activity for these subjects are shown in Fig. 6 . By 30 min after initiation of SK, total vWF antigen had increased to 150%, and by 2 h the level was 193% of pretreatment level. This rapidly appearing vWF was apparently normal and functional because it was accompanied by an even greater increase in platelet-agglutinating activity, which reached 180% of base-line level by 30 min, and remained elevated at 210-260% for the next 90 min (Fig. 6) . The plasma vWF levels in controls (who underwent cardiac catheterization or received a heparin loading dose) were unchanged. vWF antigen was also measured in small, medium, and large multimers, represented by multimers 1-4, 5-8, and 9 or larger, respectively. Although an increase in response to SK occurred in all three subpopulations of multimers (Fig. 7) , the large forms showed the greatest increase: 290% of pretreatment level by 2 h. All but two patients had increased vWF antigen levels by the end of the single SK dose; however, during the first 5-20 min of the actual SK infusion, 8 Effect ofprolonged SK infusion on plasma vWF.
Five patients in our study received SK for >12 h. In all of these patients, the initial rise in vWF antigen was sustained, but in most, the platelet-agglutinating activity declined. These changes were clearly demonstrated when the ratio of vWF platelet-aggregating activity to antigen was plotted for each patient over the course of therapy (Fig. 9 A) . There was an initial increase in the activity-to-antigen ratio (specific activity) after the SK loading dose, followed by a decline toward pretreatment level in every patient during continued SK infusion. Multimer analysis of plasmas from these patients allowed an explanation for this loss of activity: a shift in the multimer distribution occurred over time in some patients, with a progressive loss of the largest multimers and a gradual increase in smaller forms (Fig. 9, B and C) . Although the sample size is small, these observations suggest that plasmin degradation of vWF may occur during extended fibrinolytic therapy.
Discussion
Limited proteolysis is a common mechanism by which circulating proteins are activated and degraded. In vitro, FVIII is activated by thrombin (26) and inactivated by plasmin (6, 7, 9) and protein C (27) . It is presumed that these proteinases modulate the rate of fibrin formation in vivo by changing Fig. 10 A) releases the 34,000-mol wt fragment (P34), explaining the slight increase in electrophoretic mobility of the multimers (seen in Fig. 1 A as early as 5 min after the addition of plasmin). The amino-terminal sequence of P34 (Fig. 4 (9) , 118,000 and 98,000 mol wt (6) , and 155,000 and 120,000 mol wt (7) . Plasmin only slowly degrades the 134,000-and 114,000-mol wt fragments. Most of these minor or slower cleavages (thin arrows, Fig. 10 A) Fig. 10 A) and produces shorter vWF polymers which are still multiples of a nearly normal-sized, though fragmented, protomer (Fig. 10 B) . This cleavage site must therefore be very close to the interprotomer disulfide bond(s). With trypsin (Fig. 1 D) the 134,000-and 114,000-mol wt (Fig. I D) corresponds to the disappearance of multimers (Fig. 1 B) . Further cleavage of the 134,000-and 1 14,000-mol wt fragments by trypsin or plasmin parallels proteolysis of the large multimers, suggesting that the cleavage that produces shorter multimers probably occurs within these two fragments. The incomplete degradation of the multimers (and specifically their 134,000-and 114,000-mol wt fragments), despite repeat additions of plasmin, suggests that as degradation proceeds, vWF becomes progressively resistant to further proteolysis. Thus (21) circumvented this problem, and we found that SK-induced fibrinolysis was accompanied by decreases in FVIII procoagulant activity to 10-20% of its pre-SK level (Fig. 6 ).
SK effects on vWF in vivo: stimulation of vWF release and modulation of activity. In contrast to FVIII, we were unable to detect plasmin degradation of vWF in whole plasma in vitro, and therefore suspected that vWF may not be an important plasmin substrate in vivo. Nevertheless, we reasoned that if plasmin-degraded vWF multimers could be generated in vivo, we should find them in the plasmas of patients receiving SK. Surprisingly, however, rather than degradation, a twofold median increase in vWF antigen and plateletagglutinating activity occurred after a single dose of SK (Fig.  6) . Lombardi et al. (33) did not find increased vWF antigen in their urokinase-treated patients by immunoradiometric assay, but they did find an increase by rocket immunoelectrophoresis that was attributed to proteolysis of vWF. They observed a new fast-moving peak (also seen in patients with disseminated intravascular coagulation) by radio-crossed immunoelectrophoresis when eight to nine times the usual plasma load was applied and suggested this to be a minor cleavage fragment of vWF. After a 30-min SK infusion, we documented an increase in vWF antigen (Fig. 6) , which was comprised of multimers of all sizes (Fig. 7) and cannot be explained by proteolytic modification of already circulating vWF. It with severe lung injury showed an absence of slow forms and fourfold increases in rapidly migrating forms (similar to the changes observed in some patients after prolonged SK). The authors concluded that plasmin was not responsible for high vWF antigen levels because treatment of vWF with plasmin in vitro did not increase antigenicity. However, we did observe a consistent increase in vWF antigen in vivo after SK, suggesting that plasmin may contribute to the FVIII/vWF abnormalities reported in acute respiratory failure by stimulating vWF release and then causing its partial degradation.
Some of our findings may have important physiologic and therapeutic implications. First, patients treated with SK can have very high levels of vWF which might predispose to excessive platelet adhesion in areas of ulcerated endothelium that are reexposed after thrombolysis. Such platelet masses may contribute to the early reocclusions that can occur when single doses of SK or short SK infusions are used to lyse intraarterial thrombi, as in the treatment of acute myocardial infarction (30) . Secondly, plasminogen activators and/or plasmin may be very important in stimulating release and modulating the size and activity of vWF. The physiologic interactions of plasminogen activators and plasmin with the endothelium and the circulating FVIII/vWF complex deserve further investigation.
